Gene Solutions
Gene Solutions is a Vietnamese genetic testing company providing non-invasive prenatal testing, multi-cancer early detection, precision oncology, and hereditary disease diagnostics through a 2,200+ hospital partner network across Southeast Asia, with FDA Breakthrough Designation for its SPOT-MAS 10 test and a planned 2027 Hong Kong/Singapore IPO.
- Company typePrivate
- Founded2017
- HeadquartersHo Chi Minh City, Vietnam
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingServices
What Gene Solutions does
Gene Solutions is a Vietnamese genetic testing company founded in 2017 and headquartered in Ho Chi Minh City, with 501-1,000 employees and operations across Vietnam, Singapore, Taiwan, Indonesia, Malaysia, Thailand, the Philippines, and the United States. The company has cumulatively performed more than 2.2 million genetic tests across a network of 2,200+ partner hospitals and clinics, positioning itself as the leading NIPT provider in Vietnam while building a parallel oncology screening franchise. Its product portfolio spans non-invasive prenatal testing (triSure NIPT, triSure Procare, triSure Carrier, babySure), gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva), multi-cancer early detection (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, SPOT-MAS 10), precision oncology and MRD monitoring (K-4CARE, K-Track, OncoGS), hereditary cancer screening (oncoSure, oncoSure Plus, MenCare, PinkCare), and rare disease diagnostics (G4500 WGS/WES, Diagsure, CNVSure, Mitochondrial Disease).
The underlying technology stack combines cell-free DNA (cfDNA) liquid biopsy, next-generation sequencing, multi-omics analysis (genomic, transcriptomic, epigenomic), and proprietary AI/ML models trained on the largest Vietnamese genetic database. Two CAP-accredited NGS labs — one in Vietnam and one in Singapore — anchor the operation; a Pangea Laboratory partnership is extending the platform into U.S. CLIA/CAP validation, and an Element Biosciences AVITI24 collaboration upgrades the sequencing backbone. SPOT-MAS 10 received FDA Breakthrough Device Designation in May 2026, validating the platform's clinical performance (78.2% sensitivity, 99.8% specificity on a 12,281-individual real-world cohort).
Gene Solutions operates a hybrid B2B2C and direct-to-consumer model. The B2B2C channel is the dominant revenue driver: hospitals and clinics order tests, samples are processed in CAP labs, and results are returned with 5-7 day NIPT turnaround. A direct-to-consumer channel runs through genesolutions.vn, a customer support hotline, and an online results portal. Pricing is not publicly disclosed; revenue is recognized on a one-time per-test basis. The company has raised $36 million in equity across two Mekong Capital rounds (2021, 2023), secured a $200 million HSBC revolving credit facility in 2024, and is targeting a $100 million pre-IPO round in 2026 ahead of a planned 2027 listing in Hong Kong or Singapore. International expansion is being executed through regional channel partners (BDMS in Thailand, NEWCL in Taiwan, ATC Genomics in Turkey, USK Bioscience in China) and clinical validation collaborations (Pangea in the U.S., Raffles Medical in Singapore).
Gene Solutions firmographics
Firmographics- Name
- Gene Solutions
- Legal name
- Công Ty Cổ Phần Giải Pháp Gene
- Website
- https://genesolutions.vn
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Gene Solutions is a Vietnamese genetic testing company providing non-invasive prenatal testing, multi-cancer early detection, precision oncology, and hereditary disease diagnostics through a 2,200+ hospital partner network across Southeast Asia, with FDA Breakthrough Designation for its SPOT-MAS 10 test and a planned 2027 Hong Kong/Singapore IPO.
- Ownership category
- akta.pro rank
Gene Solutions industry classification
Industry- Product category
- Molecular Diagnostics and Genetic Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)
Keywords
Where Gene Solutions is headquartered
LocationHeadquarters
- HQ city
- Ho Chi Minh City
- HQ country
- Vietnam
- HQ region
- Asia
Offices5 records
Markets served
Gene Solutions business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Genetic Testing Services: Gene Solutions generates revenue primarily through providing genetic and molecular diagnostic testing services. Revenue streams include prenatal testing (NIPT, carrier screening, newborn screening), cancer screening and early detection (ctDNA-based liquid biopsy), cancer treatment guidance (oncology assays), and genetic disease diagnosis. Tests are ordered through healthcare provider partners and directly by consumers, with results returned within specified turnaround times.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No public pricing tiers available |
Go-to-market motion4 records
Distribution channels6 records
Marketing channels7 records
Gene Solutions product offering
Product offeringCore offering
Gene Solutions provides genetic and molecular diagnostic testing services through cell-free DNA (cfDNA) liquid biopsy and next-generation sequencing (NGS) technology, organized across five main categories: (1) gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis; (2) pregnancy care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal screening; (3) cancer early detection and treatment support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA analysis; (4) genetic disease diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease); and (5) hereditary disease screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL). All tests are analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore using proprietary AI algorithms optimized for the Vietnamese population.
Product overview
Gene Solutions operates a comprehensive genetic testing ecosystem organized across five main categories: (1) Gynecologic Cancer Screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis and HPV detection; (2) Pregnancy Care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal genetic screening; (3) Cancer Early Detection & Treatment Support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA and multi-omics analysis; (4) Genetic Disease Diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease) for whole genome/exome and targeted analysis; and (5) Genetic Screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL) for hereditary cancer and disease risk. The company's tests are powered by proprietary AI algorithms optimized for the Vietnamese population, analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore.
Differentiator
Problem solved
Functional benefit
Brands
- SPOT-MAS: Multi-cancer early detection blood test using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning.
- SPOT-MAS 10
- SPOT-MAS Eva
- SPOT-MAS CRC
- SPOT-MAS Lung
- K-4CARE
- K-Track
- OncoGS
- triSure NIPT
- triSure Procare
- triSure Carrier
- babySure
- epiHERA
- Cervix360
- GenCare Premium
- oncoSure
- oncoSure Plus
- GenLDL
- MenCare
- PinkCare
- G4500
- Diagsure
- CNVSure
Products and services
- SPOT-MAS 10 Multi-omic blood test for detecting cancer-associated signals across 10 cancer types in asymptomatic adults aged 40+ using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning. Validated in over 9,000 participants and used in more than 100,000 individuals in real-world settings. Demonstrated 78.2% sensitivity and 99.8% specificity in a 12,281-individual cohort.
- SPOT-MAS Eva Molecular biology test that simultaneously screens for cervical cancer and endometrial cancer from a single cervical cell sample using DNA methylation analysis (PAX1, JAM3, CDO1, CELF4 genes) combined with HPV 28-genotype detection.
- epiHERA DNA methylation-based test analyzing CDO1 and CELF4 genes to support early detection and risk stratification of endometrial cancer, designed to reduce unnecessary invasive procedures by up to 90%.
- Cervix360 Comprehensive cervical cancer risk stratification solution combining PAX1 and JAM3 gene methylation analysis with HPV genotyping, designed to reduce unnecessary colposcopies by up to 80%.
- triSure NIPT Non-Invasive Prenatal Testing (NIPT) for prenatal screening of chromosomal abnormalities using cell-free DNA from maternal blood. Optimized for the Vietnamese population using proprietary algorithms and the largest Vietnamese genetic database, with 5-7 day turnaround.
- triSure Procare Comprehensive genetic screening for common chromosomal abnormalities during pregnancy, offering more complete coverage than standard NIPT.
- triSure Carrier Preconception genetic screening test to assess carrier status for common hereditary genetic conditions before pregnancy.
- babySure Genetic testing for newborns, screening for hereditary conditions that may affect infant health.
- SPOT-MAS Blood-based cancer screening test using ctDNA (circulating tumor DNA) analysis for early cancer detection and risk assessment.
- SPOT-MAS CRC Colorectal cancer screening test using ctDNA methylation analysis for early detection of colorectal cancer.
- SPOT-MAS Lung Lung cancer screening test using ctDNA analysis for early detection of lung cancer.
- K-4CARE Precision oncology assay combining genomic and transcriptomic profiling with MRD (Minimal Residual Disease) monitoring capabilities for cancer treatment guidance and recurrence detection.
- K-Track MRD (Minimal Residual Disease) monitoring test for cancer patients to detect residual tumor cells after treatment.
- OncoGS Genomic profiling test for targeted cancer therapy selection, analyzing tumor biomarkers to guide treatment decisions.
- G4500 Whole genome sequencing (WGS) and whole exome sequencing (WES) analysis test providing comprehensive genetic information for diagnosis of genetic diseases.
- Diagsure Genetic diagnostic test organized by organ systems to help identify causes of genetic diseases and guide more effective treatment.
- CNVSure Chromosomal copy number variation analysis test for detecting abnormalities in chromosome number and structure.
- Bệnh ty thể (Mitochondrial Disease) Genetic testing for mitochondrial disorders, analyzing 37 mitochondrial DNA (mtDNA) genes to diagnose mitochondrial diseases.
- oncoSure Hereditary cancer screening test for assessing genetic cancer risk in individuals with family history of cancer.
- oncoSure Plus Comprehensive hereditary cancer screening test covering a broader range of cancer types and genetic markers than oncoSure.
- GenCare Premium Comprehensive cancer and genetic disease screening package offering broad coverage for cancer risk and hereditary conditions.
- MenCare Hereditary cancer screening test specifically designed for males, assessing risk for male-specific and common hereditary cancers.
- PinkCare Hereditary cancer screening test specifically designed for females, assessing risk for breast, ovarian, and other female-related hereditary cancers.
- GenLDL Genetic test for hereditary high cholesterol (familial hypercholesterolemia) to assess cardiovascular disease risk related to genetic lipid metabolism disorders.
Quantifiable outcome
- SPOT-MAS multi-cancer test demonstrated 78.2% sensitivity and 99.8% specificity in a real-world cohort of 12,281 individuals (2nd International Hereditary Cancers Congress 2026)
- +4 more outcomes
Companies that use Gene Solutions
Customer profileNamed customers13 records
Segments5 records
Ideal customer profiles4 records
Gene Solutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature8 records
Gene Solutions partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor, strategic, flagship and core.
- Phong Kham San Phu Khoa Hiem Muon ThS.BSNT Tran Trung HoanhminorGene Solutions signed a strategic partnership with this specialized obstetrics and gynecology clinic in Quang Tri province to expand access to precision medicine for local patients.
- My Duc Hospital System (He Thong IVF My Duc)strategicGene Solutions and My Duc Hospital System signed a strategic cooperation agreement in June 2026 to expand access to precision medicine for patients, with a focus on prenatal and reproductive genetic testing services.
- BDMS Wellness Clinic (Bangkok Dusit Medical Services)flagshipBDMS Wellness Clinic, part of Bangkok Dusit Medical Services, formed a large-scale public-private alliance to position Thailand as Asia's premier wellness economy hub. Gene Solutions participates alongside global biotech firms Illumina, Abbott, and Straumann Group, GCC partners, Thai national agencies, and academic institutions. The ecosystem integrates precision diagnostics, genomics, regenerative technology, and preventive medicine with a flagship program 'The Journey Within' combining travel, hospitality, and scientific wellness.
- ATC GenomicsstrategicATC Genomics, a Turkey-based molecular diagnostics provider with over 30 years of experience, serves as Gene Solutions' strategic partner for market entry into Turkey. At the 2nd International Hereditary Cancers Congress 2026, Gene Solutions announced its strategic entry into the Turkish market presenting real-world evidence from a cohort of 12,281 individuals demonstrating strong clinical performance.
- Pangea LaboratorycoreStrategic collaboration to validate Gene Solutions' AI-powered liquid biopsy assays (SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay with MRD monitoring) for the U.S. market. Pangea Laboratory conducts analytical and clinical validation at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides SOPs, funding, and technical support from its CAP-accredited labs in Singapore and Vietnam.
- NEWCLstrategicGene Solutions and NEWCL partnered to establish an advanced NGS laboratory in Taiwan focused on prenatal and oncology genetic testing. The move involves localizing Gene Solutions' testing platforms in Taiwan to expand healthcare access and promote genomic innovation in the region.
- Raffles MedicalminorRaffles Medical and Gene Solutions are collaborating on a project to identify patients for cancer clinical trials, leveraging Gene Solutions' ctDNA testing capabilities and Raffles Medical's clinical trial infrastructure in Singapore.
- Shenzhen USK Bioscience Co., Ltd.strategicGene Solutions and Shenzhen USK Bioscience Co., Ltd. signed an MOU in June 2025 to establish an ultra-modern NGS laboratory in southern China for advanced cancer diagnostics. The partnership targets the Chinese market for cancer genetic testing services.
- Element BiosciencescoreGene Solutions and Element Biosciences entered a strategic collaboration to enhance next-generation sequencing technologies and genetic testing services globally. The partnership leverages Element's AVITI24 multi-omics platform and Gene Solutions' extensive regional network to advance research and clinical applications in prenatal testing and cancer care.
- Vietnamese Hospital and Clinic NetworkcoreGene Solutions partners with over 2,200 hospitals and clinics across Vietnam for genetic testing services. Key partners include National Cancer Hospital Hanoi, Tam Duc Heart Hospital, Mekong Maternity Hospital, Children's Hospital 2, Hung Vuong Hospital, University of Medicine and Pharmacy Hospital HCMC, Hue Central Hospital, and Hanoi Maternity Hospital. These institutions serve as both testing sites and referral channels.
Scale indicators11 records
Recent moves8 records
Expansion highlights7 records
Gene Solutions competitors and assessment
Company assessmentDirect peers
- Prenetics Group: Hong Kong-headquartered genetic and diagnostic testing company offering NIPT, cancer screening, and consumer genetics across Asia. Direct comparable in product mix and Asian go-to-market footprint, though Prenetics is publicly listed on NASDAQ and diversified beyond pure genetic testing.
- Natera: U.S.-based genetic testing company with a strong NIPT portfolio (Panorama) and Signatera MRD oncology test. Closely comparable in the combination of reproductive and oncology liquid biopsy testing that defines Gene Solutions' portfolio.
- Guardant Health: U.S. liquid biopsy leader with multi-cancer screening (Shield) and oncology MRD products. Comparable as a cfDNA-based precision oncology company pursuing FDA validation and large-scale screening, though more mature and U.S.-focused.
Broad incumbents
- BGI Genomics: China-based global genomics leader offering NIPT, oncology testing, and NGS services at scale. Comparable as a large, low-cost Asian genomics provider competing across reproductive and oncology testing, with established SEA presence.
- Myriad Genetics: U.S.-listed genetic testing incumbent with hereditary cancer (BRACAnalysis) and oncology profiling products. Comparable as a diversified genetic testing company with strong oncology focus and established clinical channels.
- Illumina: Global sequencing platform leader whose technology underpins most NGS-based clinical tests. Indirect competitor as Gene Solutions' tech partner Element Biosciences competes directly with Illumina, and Illumina's GRAIL subsidiary competes in multi-cancer screening.
- Foundation Medicine (Roche): U.S.-based precision oncology genomics provider (Roche subsidiary) offering comprehensive genomic profiling. Comparable in oncology testing depth and the precision medicine positioning of Gene Solutions' K-4CARE and OncoGS products.
Regional players
- Novogene: China-headquartered NGS services provider serving academic, clinical, and pharma customers across Asia and globally. Comparable as an Asian NGS/cfDNA testing peer, though more focused on research services than clinical reproductive and oncology screening.
Emerging players
- Vela Diagnostics: Singapore-based molecular diagnostics company with NGS and PCR-based test menus spanning infectious disease, oncology, and reproductive health. Comparable as an Asia-headquartered competitor with overlapping NGS-based clinical diagnostics focus.
Others
- Element Biosciences: U.S.-based NGS platform company whose AVITI24 sequencing technology is integrated by Gene Solutions through a strategic partnership. Relevant as a technology partner/ecosystem enabler rather than a direct clinical testing competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Gene Solutions social profiles
Digital presenceGene Solutions compliance and trust
Trust signalCompliance2 records
Gene Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gene Solutions leadership team
Management profileNumber of profiles
Profiles3 records
Gene Solutions subsidiaries and ownership
Company hierarchySubsidiaries2 records
Gene Solutions funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gene Solutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gene Solutions
What does Gene Solutions do?
Gene Solutions provides genetic and molecular diagnostic testing services through cell-free DNA (cfDNA) liquid biopsy and next-generation sequencing (NGS) technology, organized across five main categories: (1) gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis; (2) pregnancy care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal screening; (3) cancer early detection and treatment support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA analysis; (4) genetic disease diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease); and (5) hereditary disease screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL). All tests are analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore using proprietary AI algorithms optimized for the Vietnamese population.
Is Gene Solutions a public or private company?
Gene Solutions is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gene Solutions founded?
Gene Solutions was founded in 2017. It employs 501 to 1,000 people.
Where is Gene Solutions based?
Gene Solutions is headquartered in Ho Chi Minh City, Vietnam, in the Asia region.
How does Gene Solutions make money?
One revenue line is on record: genetic Testing Services.
Who are Gene Solutions's main competitors?
Direct peers on record are Prenetics Group, Natera and Guardant Health. Broad incumbents are BGI Genomics, Myriad Genetics, Illumina and Foundation Medicine (Roche). Novogene is listed as a regional player. Vela Diagnostics is listed as an emerging player. Element Biosciences is listed as an others.
Does Gene Solutions have an API?
No public API is recorded for Gene Solutions.
What industry is Gene Solutions in?
Gene Solutions's product category is Molecular Diagnostics and Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 8071.